Microwave Ablation Versus Resection for Resectable Colorectal Liver Metastases (MAVERRIC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02642185|
Recruitment Status : Completed
First Posted : December 30, 2015
Last Update Posted : March 31, 2022
This study aims to prove that a strategy of first line local ablation of colorectal liver metastases with microwaves is not inferior to liver resections in terms of survival rates at three years with secondary endpoints being survival at five and ten years, interventional complication rates, length of stay, ablation precision measurements, need for further interventions and health-economic analysis.
A cohort of 100 patients treated with CT guided microwave ablation of 1-5 metastases <31mm in size will be followed and compared with propensity scored matched controls from the Swedish liver surgery registry - Sweliv.
The study is a multi-institutional effort by the Hepato Pancreatico Biliary (HPB) units in Stockholm Sweden, Bern Switzerland and Groningen in the Netherlands.
|Condition or disease||Intervention/treatment|
|Neoplasm Metastasis||Procedure: Microwave ablation Procedure: Resection|
|Study Type :||Observational [Patient Registry]|
|Actual Enrollment :||102 participants|
|Target Follow-Up Duration:||10 Years|
|Official Title:||Microwave Ablation Versus Resection for Resectable Colorectal Liver Metastases|
|Actual Study Start Date :||December 1, 2015|
|Actual Primary Completion Date :||January 1, 2022|
|Actual Study Completion Date :||January 1, 2022|
Patients that are primarily treated with microwave ablation of colorectal liver metastases
Procedure: Microwave ablation
CT-guided percutaneous ablation of 1-5, <31mm in diameter, colorectal liver metastases, performed with any generic microwave ablation system cleared for clinical use
Patients identified in the Swedish liver registry during the same time frame subjected to liver resection, propensity score matched to the ablation group
Open or laparoscopic resection of liver metastases using standard of care surgical procedures
- Overall survival [ Time Frame: 3 years ]
- Overall survival [ Time Frame: 5 years ]
- Overall survival [ Time Frame: 10 years ]
- Complications to treatment [ Time Frame: 1 year ]
- Disease free survival [ Time Frame: 3 years ]
- Overall cost of treatment as measured in euros [ Time Frame: 3 years ]The aggregated health provider's costs for all liver specific treatments including index surgery and hospital costs, costs for further liver specific interventions.
- Local recurrence rates [ Time Frame: 3 years ]
- Accuracy of placement of ablative device measured as mm from needle target location [ Time Frame: intraoperative ]
- Analysis of ablation volumes measured as length and radius of ovoid ablation zone. [ Time Frame: 1-28 days post intervention ]
- Need for further liver specific treatment as assessed by number of sessions with ablation or resections [ Time Frame: 5 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02642185
|University Medical Centre|
|Karolinska Institutet, Dept of Surgery at Danderyd Hospital|
|Stockholm,, Sweden, 18288|
|Principal Investigator:||Jacob Freedman, MD, PhD||Karolinska Institutet|